Abbott Laboratories +

Company

Ticker

ABT

SYK

BSX

Headquarter

North Chicago ,IL

Kalamazoo ,MI

Marlborough ,MA

CEO

Mr. Robert B. Ford

Mr. Kevin A. Lobo

Mr. Michael F. Mahoney

Industry

Medical - Devices

Stock Price

Market Cap

$227.16 B

$132.26 B

$140.69 B

Employees

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Employees

115.00 K
114.00 K
114.00 K

51.00 K
52.00 K
53.00 K

45.00 K
48.00 K
53.00 K

Y/Y

1.77%

0.87%

10.87%

1.96%

1.92%

9.76%

6.67%

10.42%

Revenue Per Employee

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Revenue Per Employee

$379.59 K
$351.83 K
$367.98 K

$361.75 K
$394.19 K
$426.32 K

$281.82 K
$296.67 K
$315.98 K

Y/Y

0.42%

7.31%

4.59%

2.73%

8.97%

8.15%

2.8%

5.27%

6.51%

Net Income Per Employee

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Net Income Per Employee

$60.29 K
$50.20 K
$117.56 K

$46.24 K
$60.87 K
$56.47 K

$15.51 K
$33.19 K
$34.96 K

Y/Y

3.66%

16.73%

134.18%

6.66%

31.64%

7.22%

38.91%

113.96%

5.35%

Income Statement

Revenue

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Revenue

$43.65 B
$40.11 B
$41.95 B

$18.45 B
$20.50 B
$22.60 B

$12.68 B
$14.24 B
$16.75 B

Y/Y

1.34%

8.12%

4.59%

7.84%

11.11%

10.23%

6.68%

12.29%

17.61%

Revenue by Products / Services

Revenue by Geography

Research and Development

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Research and Development

$2.89 B
$2.74 B
$2.84 B

$1.45 B
$1.39 B
$1.47 B

$1.32 B
$1.41 B
$1.62 B

Y/Y

5.32%

5.09%

3.76%

17.73%

4.54%

5.62%

9.88%

6.88%

14.21%

Operating Income

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Operating Income

$8.36 B
$6.48 B
$6.83 B

$2.84 B
$3.89 B
$3.69 B

$1.65 B
$2.34 B
$2.60 B

Y/Y

0.75%

22.53%

5.36%

9.95%

36.85%

5.12%

19.29%

42.09%

11.1%

Tax Rate (%)

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Tax Rate (%)

17.00%
14.00%
-91.00%

12.00%
14.00%
14.00%

39.00%
20.00%
19.00%

Y/Y

19.09%

14.58%

745.18%

3.74%

14.2%

3.33%

1059.1%

49.01%

3.48%

Net Income

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Net Income

$6.93 B
$5.72 B
$13.40 B

$2.36 B
$3.17 B
$2.99 B

$698.00 M
$1.59 B
$1.85 B

Y/Y

1.95%

17.45%

134.18%

18.25%

34.22%

5.43%

32.95%

128.22%

16.32%

Assets & Liabilities | Cash Flow

Total Assets

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Total Assets

$74.44 B
$73.21 B
$81.41 B

$36.88 B
$39.91 B
$42.97 B

$32.47 B
$35.14 B
$39.40 B

Y/Y

1.01%

1.64%

11.2%

6.51%

8.21%

7.66%

0.74%

8.21%

12.12%

Total Liabilities

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Total Liabilities

$37.53 B
$34.39 B
$33.51 B

$20.27 B
$21.32 B
$22.34 B

$14.90 B
$15.61 B
$17.39 B

Y/Y

4.18%

8.38%

2.54%

2.6%

5.19%

4.78%

4.56%

4.77%

11.44%

Capital Expenditures (Capex)

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Capital Expenditures (Capex)

-$1.78 B
-$2.20 B
-$2.21 B

-$588.00 M
-$575.00 M
-$755.00 M

-$612.00 M
-$800.00 M
-$790.00 M

Y/Y

5.73%

23.92%

0.23%

12%

2.21%

31.3%

10.47%

30.72%

1.25%

Profitability

Operating Income Margin (%)

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Operating Income Margin (%)

19.16%
16.15%
16.27%

15.40%
18.97%
16.33%

13.00%
16.45%
15.54%

Y/Y

2.04%

15.71%

0.74%

1.99%

23.18%

13.92%

24.37%

26.54%

5.53%

Net Income Margin (%)

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Net Income Margin (%)

15.88%
14.27%
31.95%

12.78%
15.44%
13.25%

5.50%
11.19%
11.06%

Y/Y

3.29%

10.14%

123.9%

9.61%

20.81%

14.18%

37.21%

103.45%

1.16%

EBITDA

2021	12742000000.00
2022	12380000000.00
2023	10605000000.00
2024	10834000000.00

2021	4646000000.00
2022	4536000000.00
2023	4934000000.00
2024	5716000000.00

2021	2518000000.00
2022	2741000000.00
2023	3453000000.00
2024	2603000000.00

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

EBITDA

$12.38 B
$10.61 B
$10.83 B

$4.54 B
$4.93 B
$5.72 B

$2.74 B
$3.45 B
$2.60 B

Y/Y

2.84%

14.34%

2.16%

2.37%

8.77%

15.85%

8.86%

25.98%

24.62%

Free Cash Flow (FCF)

2021	8648000000.00
2022	7804000000.00
2023	5059000000.00
2024	6351000000.00

2021	2738000000.00
2022	2036000000.00
2023	3136000000.00
2024	3487000000.00

2021	1316000000.00
2022	914000000.00
2023	1703000000.00
2024	2645000000.00

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Free Cash Flow (FCF)

$7.80 B
$5.06 B
$6.35 B

$2.04 B
$3.14 B
$3.49 B

$914.00 M
$1.70 B
$2.65 B

Y/Y

9.76%

35.17%

25.54%

25.64%

54.03%

11.19%

30.55%

86.32%

55.31%

Ratios

Return on Equity (ROE)

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Return on Equity (ROE)

18.90%
14.83%
28.12%

14.19%
17.02%
14.51%

3.97%
8.26%
8.51%

Y/Y

4.3%

21.53%

89.62%

5.9%

19.94%

14.75%

36.58%

108.06%

3.03%

Return on Assets (ROA)

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Return on Assets (ROA)

9.31%
7.82%
16.46%

6.39%
7.93%
6.97%

2.15%
4.53%
4.70%

Y/Y

0.96%

16%

110.49%

10.94%

24.1%

12.11%

33.44%

110.7%

3.75%

Debt to Equity

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Debt to Equity

48.29%
41.12%
31.51%

78.53%
69.89%
6.83%

52.82%
49.23%
49.36%

Y/Y

9.04%

14.85%

23.37%

6.32%

11%

90.23%

7.09%

6.8%

0.26%

Valuation

Enterprise Value

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Enterprise value

$200.30 B
$199.85 B
$203.28 B

$103.67 B
$123.70 B
$134.94 B

$74.54 B
$92.62 B
$141.77 B

Y/Y

22.67%

0.22%

1.72%

6.05%

19.32%

9.08%

9.71%

24.26%

53.05%

Enterprise value to Revenue

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Enterprise value to Revenue

4.59
4.98
4.85

5.62
6.03
5.97

5.88
6.50
8.47

Y/Y

23.69%

8.59%

2.75%

12.88%

7.39%

1.04%

2.84%

10.66%

30.14%

Enterprise value to EBITDA

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

Enterprise value to EBITDA

16.18
18.84
18.76

22.86
25.07
23.61

27.20
26.82
54.46

Y/Y

20.41%

16.48%

0.43%

3.77%

9.69%

5.84%

0.78%

1.36%

103.03%

Abbott Laboratories Competitors & Alternatives

Income Statement

Assets & Liabilities | Cash Flow

Profitability

Ratios

Valuation

Related company

Submit feedback to Bullfincher